A Open-label, Randomized, Crossover Study to Assess PK of Pregabalin
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial to compare the pharmacokinetic characteristics of
YHD1119(Pregabalin 300mg) and Lyrica capsule(Pregabalin 150mg). YHD1119 is controlled release
formulation which is made by Yuhan Corporation. Primary endpoints are Cmax,ss and AUCtau and
secondary endpoints are AUClast,ss, AUCinf,ss, Tmax,ss and t1/2.